Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 684

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 684
---
 Title:          |     | Chief Financial Officer |

[Signature page to Agreement Of Merger And Plan Of Reorganization]

Annex A-63 AMENDMENT TO THE AGREEMENT OF MERGER AND PLAN OF REORGANIZATION This Amendment, dated January 30, 2025 (this “ Amendment ”) to the Agreement of Merger and Plan of Reorganization dated November 4, 2024 (the “ Agreement ”) between Kadimastem Ltd., an Israeli publicly traded company limited by shares (“ Kadimastem ”), NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland and includes any successor company thereto (the “ NLS ”), and NLS Pharmaceuticals (Israel) Ltd., an Israeli company (and together with Kadimastem and NLS, the “ Parties ”). WHEREAS , the Parties are parties to the Agreement, and WHEREAS, the Parties desire to amend the Agreement to clarify their intentions with respect to the terms of the terms thereof. NOW, THEREFORE , for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows: 1.Section 5 is amended to add the following subsection 5.19 immediately at the end of such Section: The Parties agree that if any holder of Shares as of immediately prior to the Effective Time is entitled to receive Merger Consideration that would result in such holder owning Parent Common Stock in excess of the Beneficial Ownership Limitation (such excess amount of shares, the “ Excess Beneficial Ownership Shares ”), the Merger Consideration received by such holder shall be as provided for in Article II hereof except that any Merger Consideration in excess of the Beneficial Ownership Limitation shall be issued by Parent as pre-funded warrants exercisable for a number of shares of Parent Common Stock equal to such Excess Beneficial Ownership Shares and exercisable at an exercise price equal to par value of Parent Common Stock as of the Effective Time, which, in any event, shall be no less than CHF 0.0001 per share. The Parties maintain the rights and ability to enter into any agreements and make any necessary changes to perform the terms of this Section 5.19. 2.Section 8.10 is amended to include the following definitions of defined term: “ Beneficial Ownership Limitation ” shall mean 9.99% of the number of the Parent Common Stock outstanding immediately after giving effect to the issuance of the Merger Consideration. 3.Further,